Patients with BRAF-mutated melanoma have shown improved PFS and OS following combination treatment with these MAPK pathway inhibitors [46]; however, decreased clinical responses have been reported in patients following several months of treatment [47]. This evidence concerns the gene BRAF and melanoma.